Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives – QNT Press Release


CHENGDU, China, Sept. 5, 2022 /PRNewswire/ — Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. (“Unison”) are pleased to announce a research collaboration on an undisclosed bacterial target.

Under the terms of the agreement, Vernalis will use its expertise in drug discovery to design small molecules against this particularly challenging target, which has long been considered to be undruggable. Unison will finance all activities at Vernalis and Vernalis will be entitled to receive downstream milestones and royalties should the compounds from the collaboration progress further into development and commercialization. As part of the agreement, Vernalis has also invested in Unison’s first round of financing.

Dr. Mike WoodManaging Director of Vernalis, said: “We are extremely pleased to work with Unison on this promising and difficult bacterial target. This collaboration demonstrates once again that Vernalis is an attractive partner for biotech and pharma companies facing challenges in drug discovery. And the investment in Unison’s financing round demonstrates the flexibility of our business model and the willingness …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center